Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

Acute Lymphocytic Leukemia - Biology and Pathophysiology Poster I

Saturday, December 6, 2008: 5:30 PM-7:30 PM
Hall A (Moscone Center)
Nation-Wide Survey of Infant Leukemia in Japan: A Report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)

Takako Miyamura, MD.PhD1*, Katsuyoshi Koh, MD.PhD2*, Daisuke Tomizawa, MD3, Kanji Sugita, MD.PhD4, Koji Kato, MD.PhD5, Takashi Sato, MD.PhD6*, Yoshihiro Takahashi, MD.PhD7*, Atsushi Ogawa, MD.PhD8*, Masahiro Hirayama, MD.PhD9*, Akira Kikuchi, MD.PhD10*, Megumi Oda, MD.PhD11*, Daiichiro Hasegawa, MD.PhD12*, Kazutoshi Koike, MD.PhD13*, Yutaka Saikawa, MD.PhD14*, Michiki Hatanaka, MD.PhD15*, Keizo Horibe, MD.PhD16* and Eiichi Ishii, MD.PhD17

1Pediatrics, Okayama University Graduate School of Medicine, Okayama, Japan
2Pediatrics, University of Tokyo, Tokyo, Japan
3Pediatrics, Tokyo Medical and Dental University, Japan
4Pediatrics, Yamanashi University, Chuo, Japan
5Pediatrics, Japanese Red CrossNagoya first Hospital, Japan
6Pediatrics, Hiroshima University, Japan
7Pediatrics, Aomori Prefectural Central Hospital, Japan
8Pediatrics, Niigata Cancer Center Niigata Hospital, Niigata, Japan
9Pediatrics, Mie University, Mie, Japan
10Tokyo Children's Cancer Study Group, Japan
11Pediatrics, Okayama University Graduate School of Medicine, Japan
12Pediatrics, Hyogo Prefectual Children's Hospital
13Ibaragi Prefectual Children's Hospital, Japan
14Pediatrics, Kanazawa Medical University, Ishikawa, Japan
15Pediatrics, Fukuoka University, Fukuoka, Japan
16Clinical Research Center, National Nagoya Hospital, Nagoya, Japan
17Pediatrics, Ehime university, Japan

Prevalence and Predictors of Non-Adherence to 6-Mercaptopurine (6MP) in Children with Acute Lymphoblastic Leukemia (ALL) - a Children's Oncology Group StudyClinically Relevant Abstract

Smita Bhatia, MD, MPH1, Doojduen Villaluna, MS2*, Wendy Landier, RN, MSN2*, Alexandra Schaible, BS2*, Lindsey Hageman, MPH2*, Cara Hanby, BA3*, Wendy Leisenring, Sc.D.4*, Stephen P. Hunger, MD5, Leslie L. Robison, PhD, MPH6, Mary V. Relling, PharmD7 and F. Lennie Wong, PhD8*

1City of Hope National Medical Center, Duarte, CA
2City of Hope National Med. Ctr., Duarte, CA
3Population Sciences, City of Hope National Medical Center, Duarte, CA
4Clinical Statistics, Fred Hutchinson Cancer Research Center, Seattle, WA
5University of Colorado Denver School of Medicine and The Children's Hospital, Aurora, CO
6St. Jude Children's Research Hospital, Memphis, TN
7St. Jude Children's Rsch. Hosp., Memphis, TN
8Population Sciences, City of Hope, Duarte, CA

Increased Incidence of Osteonecrosis (ON) with a Dexamethasone (DEX) Induction for High Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report from the Children's Oncology Group (COG)Clinically Relevant Abstract

Leonard A. Mattano Jr., MD1, James B. Nachman, MD2, Meenakshi Devidas3*, Naomi Winick, MD4, Elizabeth Raetz, MD5, William L. Carroll, MD6, James A. Whitlock, MD7, Stephen P. Hunger, MD8 and Eric C. Larsen, MD9*

1Pediatric Hematology/Oncology, MSU Kalamazoo Center for Medical Studies, Kalamazoo, MI
2Pediatric Hematology/Oncology, Univ. of Chicago Comer Children's Hospital, Chicago, IL
3Children's Oncology Group, Gainesville, FL
4University of Texas Southwestern Medical Center, Dallas, TX
5Pediatric Hematology/Oncology, New York University Medical Center, New York, NY
6New York University Cancer Institute, New York, NY
7Vanderbilt University Children's Hospital, Nashville, TN
8University of Colorado Denver School of Medicine and The Children's Hospital, Aurora, CO
9Maine Children's Cancer Program, Scarborough, ME

No Influence on the Incidence of Osteonecroses When Dexamethasone Replaces Prednisone during Induction Treatment for Childhood ALL: Results of Trial ALL-BFM 2000Clinically Relevant Abstract

Anja Möricke, MD1*, Martin Zimmermann, PhD2*, Andre Schrauder, MD1*, Martin Stanulla, MD2*, Hansjörg Schmid, MD2, Rüdiger Fengler, MD3*, Michael Frühwald, MD4*, Georg Mann, MD5* and Martin Schrappe, MD1

1Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
2Pediatric Hematology/Oncology, Medical School Hannover, Hannover, Germany
3Department of Pediatric Oncology and Hematology, Charité Medical Center, Campus Virchow-Klinikum, Berlin, Germany
4Pediatric Hematology/Oncology, University Hospital Münster, Münster, Germany
5St. Anna Children's Hospital, Vienna, Austria

Outcome of Thrombosis in UKALL 2003- Anticoagulation and Re-Exposure to Aspariginase Is Feasible and Safe

Amrana Qureshi1*, Sue Richards2*, Ajay J. Vora3, Christopher D Mitchell4*, Rachel Wade5* and Nicholas Goulden6*

1Haematology, Great Ormond Street Hospital, London, United Kingdom
2Ctsu, University of Oxford, Oxford, United Kingdom
3Dept. of Pediatric Hematology, The Children's Hospital, Sheffield, United Kingdom
4Department of Paediatric Oncology, John Radcliffe Hospital, Oxford, United Kingdom
5CTSU, Oxford
6GOSH, London

A Prognostic Scoring System for Patients ≤ 60 Years of Age with Acute Lymphocytic Leukemia in First Relapse

Anjali Advani, MD1, Tao Jin2*, Brian J. Bolwell, MD1, Edward A. Copelan, MD1, Mikkael A Sekeres, MD, MS1, Ronald Sobecks, MD1, Shawnda Sungren1*, Melissa Yurch1* and Matt Kalaycio, MD1

1Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
2Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

Characteristics and Outcome of Adolescents with Acute Lymphoblastic Leukemia (ALL) Differ from Young Children in the B-Cell Lineage but Not in the T-Cell Lineage: Experience of the ALL Israeli National Studies (INS)

Ronit Elhasid1*, Gali Avrahami Sr.2*, Aya Abramov Sr.3*, Dina Attias Sr.4*, Ami Ballin Sr.5*, Bella Bielorai Sr.6*, Yoav Burstein Sr.7*, Herzel Gavriel Sr.8*, Joseph Kapelushnik Sr.9*, Hagit Miskin, MD10, Dalia Sthoeger Sr., MD11, Michael Weintraub Sr.12*, Jerry Stein Sr.2*, Isaac Yaniv Sr.13, Amos Toren Sr., MD, PhD14, Myriam Ben Arush Sr.1*, Ronit Nirel15*, Shai Izraeli Sr., MD16* and B. Stark17

1Pediatric Hemato-oncology, Rambam Medical Center, Haifa, Israel
2Pediatric Hematology-Oncology, Schneider Medical Center, Petah -Tikva, Israel
3Pediatric Hematology - Oncology, Shaarei Zedek Medical Center, Jerusalem, Israel
4Pediatric Hematology - Oncology, Bnei-Zion Medical Center, Haifa, Israel
5Pediatric Hematology - Oncology, Edith Wolfson medical center, Holon, Israel
6Sheba Medical Center, Tel Hashomer, Israel
7Pediatric Hematology - Oncology, Dana Childrens Hospital, Tel-Aviv, Israel
8Pediatric Hematology - Oncology, Ha-Emek Medical Center, Afula, Israel
9Pediatric Henatology - Oncology, Soroka Medical Center, Beer - Sheva, Israel
10Dept. of Pediatric Hematology, Shaare Zedek Medical Ctr., Jerusalem, Israel
11Pediatrics, Hem.-Onc., Kaplan Medical Center, Rehovot, Israel
12Pediatric Henatology - Oncology, Hadassah University Hospital, Jerusalem, Israel
13Schneider Children's Med. Ctr., Petah Tikva, Israel
14Dept. of Ped. Hem./Onc., The Chaim Sheba Med. Ctr., Tel Hashomer, Israel
15Statistics Department, Hebrew University, Jerusalem, Israel
16Pediatric Hematology-Oncology and Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel
17Israel

Epoetin Alfa Reduces the Need for Red Blood Cell Transfusions and Does Not Affect Remission Rate or Survival When Given to Patients with Hematologic Malignancies Receiving Hyper-CVAD TherapyClinically Relevant Abstract

Gloria Mattiuzzi, MD, Hagop Kantarjian*, Maria Cabanillas*, Maria Foudray*, Rebecca Garris*, Susan O'Brien*, Deborah A. Thomas* and Jorge Cortes*

Leukemia, UT MD Anderson Cancer Center, Houston, TX

Effect of Tight Control of Blood Glucose during Hyper-CVAD Chemotherapy for Acute Lymphocytic Leukemia

Khanh Vu1*, Sai-Ching Yeung2*, Deborah A. Thomas1, Stefan Faderl1, Marina Konopleva1*, Naifa Busaidy3*, Maria Cabanillas4*, Dushyant Verma1*, Carmen Escalante2*, Susan O'Brien1, Victor Lavis3*, Hagop Kantarjian1 and Mary Ann Weiser2*

1Leukemia, M.D. Anderson Cancer Center, Houston, TX
2General Internal Medicine, M.D. Anderson Cancer Center, Houston, TX
3Endocrine Neoplasia, M.D. Anderson Cancer Center, Houston, TX
4Pulmonary and Critical Care Medicine, M.D. Anderson Cancer Center, Houston, TX

Predictors of Osteopenia/Osteoporosis in Children with Acute Lymphoblastic Leukemia

Uma Athale, MD1, Colin Webber, MD2* and Ronald Barr, MD3

1Div. of Pediatric Hematology/Oncology, McMaster University, Hamilton, ON, Canada
2Nuclear Medicine, McMaster University, Hamilton, Canada
3McMaster University, Hamilton, ON, Canada

*signifies non-member of ASH